This trial included 691 patients with metastatic colorectal cancer previously treated with standard therapies, including fluoropyrimidine, oxaliplatin, irinotecan, anti-EGFR agents (for KRAS, NRAS, and BRAF wild-type tumors), anti-VEGF agents, trifluridine/tipiracil, and immunotherapy for MSI-H tumors. The gene discussed is NRAS; the disease is metastatic colorectal cancer.